 |
|||||
|
|||||
|
|||||
|
|||||
|
|||||
The Journal of Neuroscience, December 19, 2007, 27(51):14069-14077; doi:10.1523/JNEUROSCI.4391-07.2007
Previous Article | Next Article
Cellular/Molecular
Estradiol In Vivo Regulation of Brain Mitochondrial Proteome
Jon Nilsen, * Ronald W. Irwin, * Timothy K. Gallaher, andRoberta Diaz Brinton Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, Pharmaceutical Sciences Center, and Program in Neuroscience, University of Southern California, Los Angeles, California 90033
Correspondence should be addressed to Dr. Roberta Diaz Brinton, Department of Pharmacology and Pharmaceutical Sciences, University of Southern California, Pharmaceutical Sciences Center, 1985 Zonal Avenue, Los Angeles, CA 90089. Email: rbrinton{at}usc.edu
We used a combined proteomic and functional biochemical approach to determine the overall impact of 17β-estradiol (E2) on mitochondrial protein expression and function. To elucidate mitochondrial pathways activated by E2 in brain, two-dimensional (2D) gel electrophoresis was conducted to screen the mitoproteome. Ovariectomized adult female rats were treated with a single injection of E2. After 24 h of E2 exposure, mitochondria were purified from brain and 2D analysis and liquid chromatography-tandem mass spectrometry protein identification were conducted. Results of proteomic analyses indicated that of the 499 protein spots detected by image analysis, a total of 66 protein spots had a twofold or greater change in expression. Of these, 28 proteins were increased in expression after E2 treatment whereas 38 proteins were decreased in expression relative to control. E2 regulated key metabolic enzymes including pyruvate dehydrogenase, aconitase, and ATP-synthase. To confirm that E2-inducible changes in protein expression translated into functional consequences, we determined the impact of E2 on the enzymatic activity of the mitochondrial electron transport chain. In vivo, E2 treatment enhanced brain mitochondrial efficiency as evidenced by increased respiratory control ratio, elevated cytochrome-c oxidase activity and expression while simultaneously reducing free radical generation in brain. Results of these analyses provide insights into E2 mechanisms of regulating brain mitochondria, which have the potential for sustaining neurological health and prevention of neurodegenerative diseases associated with mitochondrial dysfunction such as Alzheimer's disease.
Key words: proteomics; Alzheimer's disease; mitochondria; biomarker; estrogen receptor; therapeutic development
Received Aug. 13, 2007; accepted Oct. 26, 2007.
Correspondence should be addressed to Dr. Roberta Diaz Brinton, Department of Pharmacology and Pharmaceutical Sciences, University of Southern California, Pharmaceutical Sciences Center, 1985 Zonal Avenue, Los Angeles, CA 90089. Email: rbrinton{at}usc.edu
This article has been cited by other articles:
J. Yao, R. W. Irwin, L. Zhao, J. Nilsen, R. T. Hamilton, and R. D. Brinton
Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease
PNAS, August 25, 2009; 106(34): 14670 - 14675.
[Abstract] [Full Text] [PDF]
L. Zhao, Z. Mao, and R. D. Brinton
A Select Combination of Clinically Relevant Phytoestrogens Enhances Estrogen Receptor {beta}-Binding Selectivity and Neuroprotective Activities in Vitro and in Vivo
Endocrinology, February 1, 2009; 150(2): 770 - 783.
[Abstract] [Full Text] [PDF]
J. W. Simpkins, E. Perez, Xiaofei Wang, ShaoHua Yang, Yi Wen, and M. Singh
The Potential for Estrogens in Preventing Alzheimer's Disease.
Therapeutic Advances in Neurological Disorders, January 1, 2009; 2(1): 31 - 49.
[Abstract] [PDF]
|
|
|
|
 |
|